NCT02426151View on ClinicalTrials.gov

Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy
Interventions
DRUG

BEPO-A

BEPO-A (Bioreactor manufacturing process)

DRUG

REPO-A

REPO-A (Roller bottle manufacturing process)

Sponsors

Lead Sponsor

LG Life Sciences
All Listed Sponsors
lead

LG Life Sciences

INDUSTRY

NCT02426151 - Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects | Biotech Hunter | Biotech Hunter